Eyenovia, Inc. (NASDAQ:EYEN) Q1 2020 Earnings Conference Call - Final Transcript
May 13, 2020 • 04:45 pm ET
Ladies and gentlemen, thank you for standing by, and welcome to the Eyenovia First Quarter 2020 Earnings Conference call with your host, Tram Bui.
Good afternoon, and welcome to Eyenovia's First Quarter 2020 Earnings Conference Call and Audio webcast. With me today are Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer and Chief Medical Officer; John Gandolfo, Eyenovia's Chief Financial Officer; and Michael Rowe, Eyenovia's Vice President of Commercial.
Earlier this afternoon, Eyenovia issued a press release announcing financial results for the 3 months ended March 31, 2020. We encourage everyone to read today's press release as well as Eyenovia's quarterly report on Form 10-Q for the first quarter of 2020, which will be filed with the SEC. The company's press release and quarterly report will also be available on Eyenovia's website at eyenovia.com.
In addition, this conference call is being webcast through the company's website and will be archived there for future reference. Please note that on today's call, we will be describing investigational products, which have yet to receive FDA approval.
Please also note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Eyenovia's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
These forward-looking statements are subject to a number of risks, including risks related to impacts of an uncertainty related to COVID-19, fluctuations in our financial results, and stock price, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; potential impacts of COVID-19 on our supply chain; risk of our clinical trials, including, but not limited to the costs, design, initiation and enrollment, which could continue to be adversely impacted by COVID-19 and resulting social distancing, timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approval for our product candidates; the potential success of our reprioritized pipeline; any protected cost savings related to our reprioritized pipeline; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our ability to timely develop and implement anticipated manufacturing, commercialization and marketing capabilities and strategies for existing product candidates; our ability to identify new products; our ability to attract and retain key personnel, intellectual property risk and others detailed and qualified by the cautionary statements contained in Eyenovia's press release and SEC filings, including its most recent annual report on Form 10-K and subsequent filings.
This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 13, 2020. Eyenovia undertakes no obligation to revise or update any